Table 5.
Cox regression analysis for prediction of OS in 245 patients with single large HCC
| Variables | Univariable analysis |
Multivariable analysis |
||
|---|---|---|---|---|
| HR (95% Cl) | p value | HR (95% Cl) | p value | |
| Age, 1 year increase | 1.01 (0.99–1.02) | 0.262 | 1.00 (0.98–1.02) | 0.944 |
| Male (vs. female) | 1.04 (0.61–1.78) | 0.880 | 1.10 (0.63–1.92) | 0.730 |
| FlB-4 index, 1 point increase | 1.14 (1.07–1.21) | <0.001 | 1.05 (0.97–1.14) | 0.201 |
| ALBl score, 1 point increase | 3.60 (2.46–5.26) | <0.001 | 2.49 (1.52–4.07) | <0.001 |
| AFP, 1 ng/mL increase | 1.00 (1.00–1.00) | 0.607 | ||
| HBV positive (vs. negative) | 1.19 (0.78–1.81) | 0.415 | ||
| HCV positive (vs. negative) | 1.28 (0.79–2.07) | 0.319 | ||
| Cirrhosis (vs. no) | 1.39 (0.91–2.11) | 0.124 | ||
| Seven-eleven criteria | ||||
| Low tumor burden | 1 | 1 | ||
| Intermediate tumor burden | 1.20 (0.71–2.01) | 0.493 | 1.27 (0.75–2.15) | 0.372 |
| High tumor burden | 2.05 (1.17–3.57) | 0.012 | 1.86 (1.01–3.41) | 0.046 |
| SR versus TACE | 0.35 (0.23–0.54) | <0.001 | 0.57 (0.35–0.93) | 0.023 |
OS, overall survival; HCC, hepatocellular carcinoma; HR, hazard ratio; Cl, confidence interval; FIB-4 index, fibrosis-4 index; ALBI score, albumin-bilirubin score; AFP, a-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; SR, surgical resection; TACE, transarterial chemoembolization.